Breakthroughs in metabolic medicine To start, 2025 brought new breakthroughs in metabolic medicine , which is good timing: almost 4 billion adults are expected to have overweight or obesity by 2050. 1. Fatty liver disease Semaglutide became the second drug approved to treat severe fatty liver disease (MASH) — probably the most interesting medical condition hardly anyone’s heard of. It’s common (5% of people), progresses in a stepwise (but interruptible) manner, and has potentially serious complications (liver cirrhosis, liver failure, cancer). The first approval for this condition was only in 2024 , but the pipeline is now red hot , with four drugs in phase 3, eight in phase 2, and three combination therapies being trailed, too. 2.LDL cholesterol It was a good year for prevention of cardiovascular disease — and particularly for PCSK9 inhibition as a mode-of-action, which stimulates the uptake of LDL cholesterol fro...
Its a web blog of Dr.Srinivasa Raju,ENT Surgeon from ELURU of A.P. Dr. C S Raju is a Member of IMA& A.P.Medical council& Association of otorhinolaryngology &Member of the Red cross society. DrCSRaju is CWC Member of IMA HQ &Past state president of IMA AP. This blog is for up dates on-" current affairs, Medical fraternity, Medico-legal information, Health care acts. The content can not be copied. please mail csrajuent10@gmail.com for all queries and suggestions.